The NK(1) receptor antagonist WIN51708 reduces sensitization after chronic cocaine.
We tested the tachykinin NK(1) receptor antagonist WIN51708 (17betahydroxy17alphaethynyl5alphaandrostanol[3,2b]pyrimido[1,2-a]benzimidazole) in a behavioral sensitization model. Rats were given 7 days of cocaine then 7 days of withdrawal to induce sensitization. Thereafter, another 7 days of cocaine with WIN51708 (2 mg/kg i.p.) given 3.5 h after each cocaine injection was given. WIN51708 reversed sensitization but had no effect on controls. NK(1) receptor antagonists may have use in stimulant abuse and schizophrenia treatment.
Davidson
Colin
C
Department of Psychiatry and Behavioral Sciences Duke University Medical Center Durham, NC 27710, USA. colda@duke.edu
Lee
Tong H
TH
Ellinwood
Everett H
EH
D000731:Androstanes / Q000494:pharmacology*; D000818:Animals; D016739:Behavior, Addictive / Q000139:chemically induced / Q000503:physiopathology / Q000517:prevention & control*; D001522:Behavior, Animal / Q000187:drug effects; D001562:Benzimidazoles / Q000494:pharmacology*; D003042:Cocaine / Q000008:administration & dosage* / Q000633:toxicity; D019970:Cocaine-Related Disorders / Q000209:etiology / Q000517:prevention & control; D008297:Male; D064729:Neurokinin-1 Receptor Antagonists; D051381:Rats; D017207:Rats, Sprague-Dawley; D018040:Receptors, Neurokinin-1 / Q000502:physiology; D013997:Time Factors
D000731:Androstanes; D001562:Benzimidazoles; D064729:Neurokinin-1 Receptor Antagonists; D018040:Receptors, Neurokinin-1; C086111:WIN 51708; D003042:Cocaine